Ligand-induced cytoplasm to nucleus translocation is a critical event in the nuclear receptor (NR) signal transduction cascade. The development of green fluorescent proteins and their color variants fused with NRs, along with the recent developments in automated cellular imaging technologies, has provided unique tools to monitor and quantify the NR translocation events. These technology developments have important implications in the mechanistic evaluation of NR signaling and provide a powerful tool for drug discovery. The unique challenges for developing a robust NR translocation assay include cytotoxicity accompanied with chronic overexpression of NRs, basal translocation induced by serum present in culture medium, and interference from endogenous NRs, as well as subcellular dynamics. The authors have developed a robust assay system for the glucocorticoid receptor (GR) that was applied to a panel of nuclear receptor ligands. Using a high-content imaging system, ligand-induced, dose-dependent GR nuclear translocation was quantified and a correlation with other conventional assays established. (Journal of Biomolecular
INTRODUCTION

T
HE NUCLEAR HORMONE RECEPTOR GENE FAMILY encodes related proteins that regulate transcription of target genes involved in development and homeostasis. Advances in the knowledge of regulation of this target class have come from studies of the function and structure of the receptors, their tissue expression patterns, and effects on important regulatory pathways, as well as changes in expression and regulation that underlie their role in diseased physiology. 1, 2 The actions of these receptors are determined by a diverse and multistep set of factors. Nuclear receptors (NRs) have been classified broadly by their ligands, the availability of ligand and coregulators (coactivators and corepressors), and the underlying protein-protein interactions and signaling events that control transcription. 3, 4 Identification and characterization of therapeutic modulators have been the focus of NR-based drug discovery efforts. Various assay methodologies have been used to identify and study NR modulators either with the full-length receptor or the ligand binding domain (LBD) of the receptor, in a cell-free or cell-based format. [5] [6] [7] [8] [9] Over the past several years, nonsteroidal receptor modulators with tissue selectivity have been identified for many NRs, which offer the potential for improved pharmacological profiles over synthetic steroids as therapeutic agents. 10, 11 Upon ligand binding, some members of the steroid hormone receptor family, such as the glucocorticoid receptor (GR), the androgen receptor (AR), and the mineralocorticoid receptor (MR), translocate from the cytoplasm to the nucleus, where they bind to their specific hormone response elements in the promoter of their target genes and activate transcription. Other NRs, such as the estrogen receptor (ER), the progesterone receptor (PR), the heterodimeric receptors such as the vitamin D receptor (VDR) and the retinoid X receptor (RXR), and some orphan nuclear receptors (oNHRs), are predominantly located in the nucleus in the absence of ligand.
The use of the green fluorescent protein (GFP) 12, 13 to construct fusion proteins allows real-time analysis of intact cells and extends the potential assay formats for steroid hormone receptors to include nuclear translocation for the identification of agonists and antagonists. 14 The unliganded GFP-GR fusion is completely localized in the cytoplasm and rapidly translocates to the nucleus in a ligand-dependent manner with ligand specificity similar to that of the native GR. 15 Several investigators have shown subcellular trafficking of NRs, including AR and MR in various cell lines, 16, 17 and work by Nishi et al. 18 using fluorescence resonance energy transfer (FRET) microscopy has shown that, upon translocation to the nucleus, GR and MR can form heterodimers. Other receptors such as ER, which are predominately localized in the nucleus in the unliganded state, undergo an alteration in receptor distribution within the nucleus from a uniform GFP-ER pattern to a punctuate pattern upon ligand addition. 19 The ligand-induced intranuclear reorganization of ER, although not as dramatic as the cytoplasmto-nuclear translocation of AR and GR in response to their corresponding ligands, is a measurable signaling event with important physiological consequences. Subcellular trafficking of regulatory components can be imaged and quantified using high-content screening (HCS) technology. This technology consists of sophisticated image analysis algorithms that can convert images obtained by automated fluorescence microscopy into quantitative numerical data. This enables the quantification of translocation events, subcellular distribution of proteins, object intensity, and shape changes on a cell-by-cell basis. HCS technology has been used for phenotypic screening and compound mechanism-of-action studies, and it has opened up a new biology-driven approach to drug discovery. 20, 21 We describe here the development and validation of a GR nuclear translocation assay for ligand mechanism-of-action studies. This assay has also been extended to include AR translocation. Ligand-induced cytoplasm-to-nucleus translocation is an early step in the transcription process and can be used to identify agonists, antagonists, and other modulators of the receptor, and it can be evaluated in a variety of cellular backgrounds. Because chronic overexpression of NRs could potentially be unhealthy to the host cells, a protocol using yellow fluorescent protein-GR (YFP-GR) transiently expressed in COS-7 cells was developed and validated.
Using the Cellomics ArrayScan™ HCS system (www.cellomics.com), ligand-induced GR nuclear translocation events were imaged and quantified. Dexamethasone (Dex) induced a rapid, robust, and dose-dependent cytoplasm-to-nucleus GR translocation in COS-7 cells transfected with the YFP-GR plasmid. The EC 50 for Dex in the translocation assay was 2 to 3 nM, which is in close agreement to the results reported from a wholecell Dex binding assay. 22 These results supported the use of a GR high-content nuclear translocation assay for compound mechanism-of-action studies. We have used this assay to evaluate a library of known steroids in a high-throughput screening (HTS) mode. Our data indicate that this is a robust assay, miniaturized to a 384-well format, that is amenable for screening larger collections of compounds when integrated on an automated screening system. 23 We also compare and discuss assay correlation between translocation, ligand binding, and cell-based transactivation assays. Finally, the assay demonstrates the utility of GFP fusions and the use of transient transfection assays for imagebased HCS for drug discovery.
MATERIALS AND METHODS
Chemicals and reagents
Known steroids (prednisolone, prednisolone-21-acetate, hydrocortisone, triamcinolone acetonide, flunisolide, budesonide, progesterone, RU-486 [mifepristone], spironolactone, corticosterone, dexamethasone, β-estradiol) were obtained from Sigma-Aldrich (St. Louis, MO) and geldanamycin from EMD (San Diego, CA). All cell culture media and reagents were obtained from Invitrogen (Rockville, MD). Charcoal/dextran-treated fetal bovine serum was obtained from Hyclone (Logan, UT), fetal bovine serum from Invitrogen, and FuGENE 6 from Roche Applied Sciences (Indianapolis, IN). Molecular biology reagents were from Invitrogen Life Technologies (Rockville, MD), BD Biosciences Clontech (Mountain View, CA), and Qiagen (Valencia, CA).
Black, clear-bottom, tissue culture-treated 384-well assay plates (Falcon #3962) for the translocation assay were obtained from BD Biosciences (Franklin Lakes, NJ), and 96-well, white clear-bottom plates for the luciferase assays were obtained from Corning (#3903) (Corning, NY). The 1536-well, black solid plates (PerkinElmer #60052358) for the fluorescence polarization (FP) assay were obtained from Greiner Bio-One (Longwood, FL).
Formaldehyde (37%, v/v) was purchased from J. T. Baker (Phillpsburg, NJ), and Hoescht 33342 was purchased from Molecular Probes (Eugene, OR). The luciferase Steady-Glo reagents were from Promega (Madison, WI), and PMA was from EMD (San Diego, CA).
Preparation of recombinant fusion protein constructs
The coding regions of the human GR (NM_000176) and the human AR (NM_000044) were cloned using reverse transcriptase PCR (RT-PCR) as follows.
A set of human RNA was commercially obtained from BD Biosciences Clontech (bone marrow, brain, colon, heart, kidney, liver, lung, mammary gland, ovary, pancreas, placenta, prostate, skeletal muscle, small intestine, spleen, stomach, testis, thymus, thyroid, uterus), and cDNA was prepared according to the manufacturer (SuperScript First-Strand Synthesis System for RT-PCR, Invitrogen Life Technologies). For the PCR reactions, the individual cDNA preparations were pooled, and an aliquot of the mixture was used (approximately 50-ng input RNA/100-µL reaction).
For PCR amplification, a premix volume of 600 to 800 µL was set up and distributed into 12 wells for a gradient thermocycler reaction (Eppendorf, Mastercycle Gradient) with between 50 and 70 µL per well. For the reaction, Pfu polymerase and buffer conditions were used according to Stratagene's directions except that DMSO to a final concentration of 10% was added. PCR conditions were as follows: initial 2 min at 95 °C, 40 cycles at 95 °C, 30 s; gradient midpoint at 60 °C with ±2 °C difference per well (spanning approximately between 50 °C and 70 °C) as annealing temperature for 1.5 min, and 2.5-min elongation at 72 °C. This was followed by a final 10 min at a 72 °C incubation step.
PCR products were gel isolated using the QIAquick Gel Extraction Kit from Qiagen and cloned into the pENTR/D-TOPO vector according to Invitrogen Life Technologies. After sequence verification, the clones were combined with the desired expression vectors using the Gateway LR Clonase enzyme mix according to the manufacturer's directions.
Vectors used for expression are derivatives of pcDNA3.1 modified to use the gateway technology. Specifically, the Ntermini have either eGFP or YFP (BD Biosciences Clontech) followed by the gateway conversion cassette to allow in-frame N-terminal tagging.
Primers were designed according to the pENTR Directional TOPO Cloning KIT. The primers used are as follows:
Primers for GR: "forward primer" CACCTATGGATCC-TATTCACTGATGGACTCCAAAGAATCATTAACTCCTG and "reverse primer" ATTAAGGCAGTCACTTTTGAT-GAAACAGAAGTTTTTTGATATTTCCATTTG Primers for AR: "forward primer" CACCGGATCCAGCTCAAG-GATGGAAGTGCAG and "reverse primer" AAGCTTTCA-CTGGGTGTGGAAATAGATGGGCTTGACTTTCCCAGAA AGG.
Cell culture
Translocation assay. For all the translocation experiments, COS-7 cells were maintained in RPMI 1640 supplemented with 5% fetal bovine serum in a 5% CO 2 incubator at 37 °C. Prior to transfection, the cells were seeded in assay medium, which consisted of phenol red-free RPMI 1640 media (supplemented with 5% charcoal/dextran-treated fetal bovine serum).
Reporter assay. Hela cells (human cervical adenocarcinoma) were stably transfected with a chimera receptor joining the Gal 4 DNA binding domain and human GR ligand binding domain, as well as a plasmid that contained a Gal 4-luciferase reporter gene. The resulting stable cell line, NP-1, was maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% charcoal-treated fetal bovine, 1% penicillin/streptomycin, 1× MEM nonessential amino acids, 1 mg/mL G418, and 0.3 µg/mL purimycin. For the assay, cells were seeded into assay plates in assay media that were the same as cell culture medium without G418 and purimycin and containing DMEM high glucose without phenol red.
Optimization of a transient transfection protocol
A transient transfection protocol was developed and optimized for the GR translocation assay in COS-7 cells and further expanded to include AR translocation. To shorten the time between the introduction of the DNA construct into the cells and compound stimulation, as well as to lower the background (complete serum can induce GR translocation to the nucleus), COS-7 cells were seeded directly into P75 flasks (2,000,000 cells/P75 flask) in assay medium and incubated at 37 °C with 5% CO 2 for 16 h before transfection. The media were then replaced with fresh assay media prior to transfection and the cells transfected with a mixture of diluted FuGENE 6 and pcDNA3-YFP-GR. For each flask, the transfection mixture was prepared by mixing 30 µL of FuGENE 6 into 500 µL of phenol red-free, serum-free RPMI medium followed by the addition of 10 µg of pcDNA3-YFP-GR. The mixture was then incubated at room temperature for 15 min before the addition of 500 µL of phenol red-free, serum-free RPMI medium and the subsequent overlaying of the transfection mixture onto the cells. The transfected cells were incubated at 37 °C for 6 h, trypsinized, and seeded into 96-well plates (5000 cells per well in 90 µL of assay media) or into 384-well plates (2000 cells per well in 25 µL of assay media). Cells were incubated for an additional 16 h at 37 °C, 5% CO 2 before stimulation with compounds.
Image acquisition and analysis
Transfected COS-7 cells plated in 384-well plates were treated with compounds diluted in water/DMSO to give a final assay concentration of 1% (v/v) DMSO. Then, 5 µL of compound was transferred to the cell plates using a 384-well CyBi™ (CyBi Inc., Woburn, MA) into columns 1 to 20 with the appropriate concentration of DMSO in columns 21 to 24. Dex (100 nM) was included on each assay plate in column 23 as an internal control. Initially, different time points poststimulation (5-150 min) were evaluated, but 1 h was chosen as the optimal incubation time point for ease of plate processing. The cells were fixed by adding 25 µL of fixation buffer (3.7% v/v formaldehyde containing 10 µg/mL Hoechst 33342 in Dulbecco's phosphate-buffered saline [DPBS]) directly onto the assay medium and incubated for 15 min at room temperature followed by 2 washes with DPBS.
This was followed by the addition of 50 µL DPBS to the cell layer, and the plates were sealed with a transparent plate seal (PerkinElmer #6005185). Imaging was carried out using the Cellomics ArrayScan IV™ High Content System (Pittsburg, PA) equipped with a Xenon-arc lamp. YFP fluorescence images were acquired with a 10× Plan Fluor 0.5 numerical aperture objective using Omega dichroic Emitter Pair XF104 filters with an excitation λ = 500 nm (25-nm bandpass) and an emission λ = 545 nm (35-nm bandpass). The nuclear translocation BioApplication (version 2) was used for image analysis. The difference in fluorescence intensity between the cytoplasm and the nucleus was used to quantify the nuclear translocation event. Data were analyzed using a customized HTS data analysis software package. IC 50 values were determined using curve-fitting software XL-Fit (IDBS Inc., Emeryville, CA).
High-Content Glucocorticoid Receptor Translocation Assay
Luciferase assay
Luciferase assays were performed according to the manufacturer's instructions (Promega) with the slight modification of reducing the volume of substrate added to the cell plate. The NP-1 assay was used to identify agonists or antagonists of the human GR ligand binding domain. Activation of the receptor chimera transactivates the Ga14 luciferase reporter in a stable Hela cell line. Cells were seeded at 10,000 cells per well into 96-well, white clear-bottom plates and incubated overnight in assay media. For agonist assays, compounds were added and plates incubated in a cell culture incubator for 18 h at 37 °C, 5% CO 2 . For antagonist assays, after compound addition, 10 nM final concentration of Dex was added before incubation. Luciferase activity was measured after a 20-min incubation with the addition of Steady-Glo reagents and read on the Envision™ plate reader (PerkinElmer, Boston, MA). The agonist effect of compounds was normalized and expressed as 100 × (Sample -Blank)/(Total -Blank); the antagonist effect of the compounds was normalized and expressed as 100 × [1 -(Sample -Blank)/(Total -Blank)]. The Sample is defined as the luciferase activity in the presence of a test compound; Blank is referred to as the luciferase activity in the presence of the DMSO control, and Total represents the signal induced by 100 nM Dex.
Fluorescence polarization assay
The GR competition assay was purchased from the Invitrogen Corporation (Madison, WI) as a complete kit (#2893) that included buffer, ligand, and protein. This assay uses a TAMARAlabeled tracer, Fluoromone™ GS Red, which binds to the human recombinant GR with a K d of 0.3 nM. The assay was carried out in the presence of a GR-stabilizing peptide as specified in the protocol supplied by the vendor. The fluorescence polarization measurement was taken using the ViewLux™ Imaging System (PerkinElmer) at an excitation λ = 525 nm (20-nm bandpass) and an emission λ = 598 nm (25-nm bandpass).
To prevent compound carryover due to the potency of the known steroid compounds, an acoustic dispensing system from Labcyte Inc. (Sunnyvale, CA) was used to transfer the compounds in 100% (v/v) DMSO into the 1536-well assay plates as 40-nL aliquots in quadruplicate on the same plate. This system uses acoustic wave energy applied to the bottom of a multiwell plate to transfer droplets of fluid from a source plate to the assay plate. 24 Compounds were titrated to calculate concentration response curves (CRCs) in 10 half-log serial dilutions starting at a final concentration of 1 µM. All other reagents (buffer, 4 nM GR, 1 nM Fluoromone™ GS Red) were delivered using the Flexdrop liquid dispenser (PerkinElmer) in a total volume of 8 µL. The plates were incubated at room temperature for 2 h prior to imaging on a Viewlux™. Polarization was calculated as millipolarization units (mP), and the data were analyzed using a customized HTS data analysis software package. Inhibition was expressed as 100 × [1 -(Sample -Blank)/(Total -Blank)], where Sample is the activity of the test compounds, Blank is the activity of the DMSO control, and Total is the activity in the presence of 1 µM Dex.
RESULTS AND DISCUSSION
Live-cell imaging of the YFP-GR nuclear translocation event YFP-GR was transiently transfected into COS-7 cells, and the GR agonist Dex was used to perform proof-of-concept assays to validate the nuclear translocation method. COS-7 cells were chosen for these experiments because they express low levels of endogenous corticosteroid receptors, which could contribute to increased background and slower nuclear translocation rates. 16 In addition, 5% charcoal/dextran-treated fetal bovine serum (FBS) was used to eliminate any endogenous corticosteroid ligand that may be found in FBS. The COS-7/YFP-GR cells exhibited strong fluorescence in the cytoplasm that was independent of ligand. Real-time GR cytoplasm-to-nucleus translocation following Dex stimulation in COS-7 cells expressing YFP-GR was first observed using a Nikon Eclipse TE300 microscope with a camera by recording images at 30-, 60-, 240-, and 480-s intervals (Fig. 1) . Nuclear translocation of GR was rapid, and the kinetics of GR translocation was similar to that initially reported by Htun et al. 15 in murine adenocarcinoma cells (1471.1) and more recently by Funato et al. 25 in SY5Y cells. Furthermore, Nishi et al. 18 demonstrated that transiently transfecting GFP fusion proteins (GR and MR) into COS-1 cells maintained their functional abilities as well as expression patterns and molecular masses. Although there are commercially available cell lines stably expressing GFP-GR, we have not evaluated the utilization of these stable cell lines. In general, we believe that stable cell lines have advantages over transient transfection for HTS and HCS when constitutive overexpression of target proteins does not result in cell growth inhibition. However, when overexpression of target proteins causes inhibition of cellular growth, transient transfection is a reasonable approach. In the case of NRs, when multiple NRs are used to evaluate ligand specificity, using the same parental cell line transiently transfected with the NR of interest not only is convenient but also provides the identical cellular context for comparison of NR signaling.
Image analysis and quantification of the Dex-induced YFP-GR translocation
Compound-induced translocation for the GR-YFP fusion protein was quantified from triplicate wells after image acquisition at ×10 magnification using the Cellomics ArrayScan™. The nuclear translocation BioApplication was used for analysis of acquired images and calculation of the nuclear-cytoplasmic differences in YFP fluorescence. 26 This system was used to scan multiple fields in each well to obtain images from a minimum of 500 cells per well. Hoechst staining was used to indicate the position of the nucleus. Quantification of the amount of YFP staining found in the nucleus was determined from the intensity of yellow fluorescence averaged over the region identified by the Hoechst stain. To delineate a representative region of cytoplasm, an annular ring 4 pixels wide was drawn around the nuclear boundary where GR-YFP is primarily in the cytoplasm of unstimulated cells. The difference in fluorescence intensity between the cytoplasm and the nuclear region was calculated for each cell and then averaged across all cells imaged per well. EC 50 values were calculated from the well-averaged data under each assay condition. Figure 2A shows representative images from unstimulated and 100-nM Dex-stimulated cells. In unstimulated cells where there is a low level of GR activation, the GR-YFP is primarily in the cytoplasm. This is hallmarked by the presence of cells with nuclear regions that show low YFP fluorescence. In Dexstimulated cells, YFP-GR is present primarily in the region corresponding to the nucleus (Fig. 2A) . This agrees well with the previously reported observations. 27 To determine the time course of YFP-GR translocation for Dex, a potent GR ligand, the EC 50 was determined after 0.25 to 4 h of treatment (Fig. 2B) . Potent effects of Dex were evident by the 0.25-h measurement. These data are in agreement with previous studies in GR-GFP transiently transfected COS cells where Dexinduced translocation was evident as early as 5 min after ligand addition. 28 The Y maximum for each time point, which converges and plateaus by 1 h of incubation, would suggest that translocation was complete, but apparent potency of Dex increases with increased Dex treatment time. The log (EC 50 ) determined for Dex was linear after 1 h of Dex incubation (Fig. 2C) . Compound incubation was therefore standardized to 1 h for future experiments. The time course of ligand stimulation that we observed has been confirmed by extensive studies reported on GR, 16, 18, 27 MR, 16, 18, 29 and AR 17,30 translocation.
Geldanamycin effects on nuclear translocation
To further validate the nuclear translocation assay, we decided to compare agonist-induced and antagonist-induced GR translocation, as well as investigate the effect of chaperone proteins such as heat shock protein on GR translocation. As shown in Figures 1 and 2 with the transient expression of YFP-GR in COS-7 cells, GR resides in the cytoplasm in the unliganded state. There it associates with multiprotein chaperone complexes that contain heat shock proteins (Hsp90/Hsp70), as well as other proteins such as immunophilins and FK-binding proteins. 31, 32 The addition of the agonist Dex results in a rapid translocation of YFP-GR from the cytoplasm to the nucleus in which a hyperspeckled pattern is initially seen at 0.5 h (Fig. 3A) . The observation of this hyper-speckled pattern is compound concentration and time dependent, and it is not consistently observed throughout the population of transfected cells. This could be due to the varying levels of expression of the YFP-GR in the transiently transfected COS-7 cell population. In fact, the effect of protein expression level on NR translocation has been previously reported. Using fluorescence recovery after photobleaching (FRAP) experiments, Marcelli et al. 17 observed a decrease in mobility with high expression levels of GFP-AR as compared to low expression levels in response to agonist treatment. No difference in mobility was observed with antagonist treatment. Because of the inconsistent observation of this hyper-speckled pattern in our transiently transfected cell population, we could not use this parameter to quantify intranuclear conformational changes. As shown in Figure 3A , the effect on GR translocation by the antagonist, RU486, was at a slower rate than that for the agonist Dex, and a diffused YFP pattern was observed. Translocation was complete around 2 h in the presence of RU486 as compared with Dex, which was complete at approximately 1 h, as determined from CRCs over time (Fig. 2B) . Similar to the response to Dex, the rate of GR translocation in response to RU486 was also concentration dependent; at higher concentrations, translocation was rapid but slower at lower concentrations. Because of the variation of protein expression levels and the dependency on compound concentration, especially with antagonists, the selection of a 1-h compound treatment time described above for compound screening is appropriate. Using the YFP-GR transient transfection translocation assay, we investigated whether Hsp90 inhibitors such as geldanamycin (GA) could distinguish agonist from antagonist activity. To ensure complete translocation of GR into the nucleus, a 1-h compound incubation of Dex or RU486 at 60 nM was chosen. GA (1 µg/mL) was added either 1 h after ligand treatment or 15 min prior to ligand treatment. As shown in Figure 3B , GA addition after ligand incubation reduced the GR translocation by 12% for Dex but caused a 46% reduction in the presence of RU486, confirming the slower rate of antagonist-mediated translocation. Pretreatment with GA for 15 min prior to ligand addition resulted in a 54.5% and a 91.9% reduction in GR translocation for Dex and RU486, respectively. Therefore, GA significantly blocked the antagonistinduced translocation of GR. In agreement with this observation, previous reported work on the effect of GA on AR translocation suggests that antagonists induce a different AR conformation and that antagonist-bound AR remains associated with Hsp90 even upon translocation. 17 Heat shock proteins form a heterocomplex with GR in the cytoplasm and are translocated into the nucleus upon ligand induction. GA acts by inhibiting the adenosine triphosphate (ATP)-dependent conformational change of Hsp90 in the cells, which is required for nuclear receptor binding. 33 Using immunofluorescence techniques, Czar et al. 34 have shown that GA inhibits the GR trafficking to the nucleus by destabilizing receptor-bound Hsp90 complexes, whereas Tago et al. 35 reported that Hsp90 also regulates nuclear retention of GR. Recently Kakar et al. 36 identified an export motif in the LBD of GR that binds heat shock proteins in the cytoplasm. A truncated GR without the export motif showed mostly nuclear localization, suggesting a role for Hsp90 in subcellular localization of the receptor. However, the key proteins involved in the chaperone complex of shuttling nuclear receptors across the nuclear membrane still need to be clearly defined.
Assay validation
Based on the initial results during the development of the assay, we decided to carry out a small validation screening run containing nine 384-well compound plates to determine assay robustness and reproducibility across multiple plates. COS-7 cells were transiently transfected with the YFP-GR plasmid as described in Materials and Methods. For the validation run, transfected cells were dispensed into the assay plates using a Multidrop. Test compounds or DMSO controls (1.0% v/v) were added and incubated for 1 h at 37 °C, after which the plates were fixed and washed with a plate washer. Nuclear translocation was imaged, and the nuclear-cytoplasmic intensity difference was calculated. As shown in Figure 4 , the average signal (induced by 100 nM Dex) to background (DMSO) ratio was >7, with an average Z′ > 0.6. Both the signal-to-background (S/B) ratio and the Z′ were consistent across the plates within the run and were maintained in experiment runs after validation. The use of the plate washer after fixation did not affect the performance of the assay across the multiplate validation run, as measured by the Z′. The Z′ is a statistical measurement of the signal window as a fraction of the distance between the means of the distribution. A perfect Z′ is 1, and an acceptable Z′ should be greater than 0.5. 37 The HCS GR translocation assay is economical to run, with an estimated cost per well in a 384-well format of $0.04. This includes the cost of transfection reagents, cell culture, assay plates, and buffers. Throughput was approximately 10,000 data points per instrument per day. The rate-limiting step in running an HCS screen is the scanning speed of the imager. Newer imagers that can scan and acquire images simultaneously such as the Evotec Opera (www.evotectechnologies.com; PerkinElmer, Waltham, MA) will extend HCS assays into HTS capacity.
Correlation between GR binding, translocation, and transactivation
Activation of the GR receptor is a multistep process. Prior to hormone binding, GR resides in the cytoplasm heterocomplexed with heat shock proteins. Upon ligand binding, GR translocates to the nucleus. In the nucleus, one of the functions of GR is to bind to DNA promotor elements, which in turn activates or represses transcription. Ligand-activated DNA binding results in transactivation of the promoters containing GRresponsive elements (GRE), which contributes toward the glucocorticoid side effects associated with steroid therapy. Development of a safer GR modulator would result in little or no GR-mediated transactivation of GR-dependent genes, thus significantly improving the therapeutic ratio compared to currently used steroids. Discovery of new GR modulators requires assessment of the entire activation and translocation process. A panel of known GR ligands was assessed using a FP competition assay and a cellular transcriptional transactivation assay. The results obtained were correlated to the GR translocation assay.
The FP competition assay measures binding to a purified recombinant GR receptor via displacement of a red-shifted labeled glucocorticoid ligand. The red-shifted ligand was used to reduce compound interference due to intrinsic compound fluorescence. The FP assay was run on a fully automated system in a miniaturized 1536-well format to reduce reagent consumption and decrease costs. The assay was validated by determining 1) stability of the reagents on the robotic system, 2) the consistency of the assay window over multiple runs, and 3) the Z′ factor. The GR FP assay was robust with a coefficient of variance for the totals (Dex) of 3.9% and the blank (DMSO) of 10.5% and an average Z′ of 0.68. The GR reporter cell line H-Gal hGR NP1-1 was obtained from H. Gronemeyer (IGBMC, Strasbourg, France). The receptor is a chimera between the GAL4 DNA binding domain and the human GR ligand binding domain. Upon binding ligand, the chimera activates the cognate (17-mer) 5-β-globin promoter in front of luciferase. The assay identifies compounds that promote binding of the chimera to the GAL4 DNA binding site in the β-globin promoter. Transcriptional activity with 10 nM Dex in a final DMSO concentration of 0.1% for 20 h at 37 °C in 5% CO 2 resulted in a 9.5-fold S/B ratio in the agonist assay and a 8-fold S/B ratio in the antagonist assay. This assay was robust with an average Z′ > 0.8 in both assay formats. Table 1 compares the results of the GR multistep process of binding, translocation, and transactivation for 10 known steroids. The FP competition assay uses purified human recombinant glucocorticoid receptor, and results for selected ligands such as estradiol and corticosterone are more potent than previously described using crude extracts. 7 Results from the binding and transactivation assays support the data obtained from the YFP-GR translocation assay in COS-7 cells in that the same rank order of potency was observed for the 10 known steroid agonists tested. The potency measurements obtained for all molecules tested showed significant (p < 0.05) correlation between GR translocation and Dex displacement in the binding assay. The Spearman rank correlation coefficient between these 2 variables was 0.7. The transactivation assay permits discrimination between GR agonists and antagonists. Potency determinations from the translocation assay were highly correlated (p < 0.01) with potency measurements from the transactivation assay in the agonist mode. An EC 50 for GR translocation was measured for 2 (progesterone and RU486) of the 3 antagonists tested. At the 1-h compound incubation time point and concentration range tested, β-estradiol did not give an EC 50 value. Rank order of the antagonists was apparent between the 3 assay formats. However, there was a greater difference in antagonist potency measured between the 3 assays than for the agonists. EC 50 values obtained for several agonists in the HCS GR translocation assay under screening conditions were similar to the EC 50 values reported for GR translocation using an enzyme fragment complementation assay. 38 Data presented here agree with Pariante et al. 39 that RU486 and Dex both show similar potent binding to GR and the ability of RU486 to induce GR translocation. However, RU486 is less effective at promoting nuclear translocation, and the potent antagonist effect seen in the transactivation assay is the result of inhibition of nuclear GR effects.
Cross-talk and ligand specificity of NRs
To determine ligand specificity and better understand crosstalk between nuclear receptors using our assay format, nuclear translocation assays for AR, ERα, and ERβ were performed using their known steroid ligands. After transfection in COS-7 cells, the YFP was predominately observed to be cytoplasmic for GR and AR prior to ligand addition, and upon stimulation, translocation to the nucleus was observed. For both ER isoforms, the YFP was observed in the nucleus upon transfection regardless of ligand stimulation (data not shown). Previous studies by Tanaka et al. 28 confirmed that overexpression of YFP-MR did not contribute to the nuclear expression of the protein. Our transient assay system is in agreement with these findings that without ligand treatment for YFP-GR and YFP-AR, no nuclear translocation was observed.
Glucocorticoid and mineralocorticoid are 2 classes of the adrenal corticosteroid hormone that exert different physiological responses but act through similar receptors and DNA response elements. GR has the closest peptide homology to MR than to PR or AR in all species. 40 This similarity of receptors is most apparent by looking at common ligands. To determine the effect of ligand treatment and cross-talk among steroid hormone receptors, YFP-GR and YFP-AR were transiently transfected into COS-7 cells as discussed in Materials and Methods. Exposure of the cells for 1 h at 100 nM Dex, R1881 (the synthetic androgen), and aldosterone (the MR ligand) resulted in the nuclear translocation of the YFP fusion proteins that was concentration dependent, as seen in Figure 5 . For AR, the EC 50 for R1881 was 0.28 nM, but activity was observed for GR (>300 nM). The curve for R1881 on the nuclear translocation of GR was not classic and showed no plateau at the highest concentration tested of 0.33 µM. Recently, R1881 was observed to have potent antagonist activity for MR (0.75 nM) by antagonizing the aldosterone-induced MR transactivation activity. 41 Aldosterone has high affinity for GR translocation (36.3 nM) and no activity on AR translocation. 42 Nuclear translocation in response to Dex for GR was consistent with previous results, but Dex was ineffective at promoting AR nuclear translocation.
We then used the transient assay format in COS-7 cells to assess the specificity of a panel of known steroid ligands, both agonists and antagonists, for GR and AR receptors, as well as MR agonists and antagonists. As can be seen in Figure 6 , known steroid ligands were incubated for 1 h posttransfection at a 100-nM final concentration in 1% DMSO (v/v), scanned on the Cellomics ArrayScan™, and calculated as percentage control referenced to DMSO treatment. The rank order of ligands 
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with respect to potency on AR translocation was R1881 > RU486 > β-estradiol > spironolactone > progesterone > budesonide, followed by the antagonists casodex and hydroflutamide (Fig. 6A) . One possibility for the low antagonist activity seen here and reported by others is that translocation to the nucleus for antagonists is at a slower rate and was incomplete at the 60-min compound incubation time used in these experiments and at the concentration tested. 17 This is similar to our previous results looking at the antagonist activity of RU486 on GR translocation (Fig. 3) . In our hands, the EC 50 for RU486 on AR translocation, which has been found to have AR agonist activity, was 6.23 nM as compared to 0.19 nM for R1881 in these experiments. The relative affinities of RU486 and R1881 in this assay differ by a factor of 32, which is in agreement with the transactivation results reported by Song et al. 43 In addition, besides RU486, only progesterone showed any significant crossreactivity with both AR and GR. Progesterone, along with β-estradiol, has been reported to be transactivation competent in an AR-dependent promoter assay. 29 Next we monitored GR selectivity on nuclear translocation for the panel of known steroids at 100 nM. As shown in Figure 6B , GR translocation under the same conditions showed equal affinity for Dex, prednisolone, corticosterone, budesonide, and RU486 and lower affinity for aldosterone, R1881, progesterone, spironolactone, and β-estradiol. The higher affinity ligands showed similar efficacy at 100 nM and translocated >90% of the GR receptor. The biological response of a ligand, especially that of antagonists and their effect on translocation, may be due to different regulatory factors. These include immunophilins and immunophilinlike phosphate PP5, as well as chaperone proteins such as Hsp70, Hsp90, Hsp40, p23, and NLS. 31, 44 Thus, the continuous shuttling of proteins across the nuclear membrane is a complicated process. Our assay system detected ligands of both high and low affinity, which demonstrates that this assay could be used in a screening format for the identification of novel nuclear receptor modulators.
CONCLUSIONS
Engineered chimeras for constitutive nuclear receptors such as the THR, VDR, ER, and orphan receptors can be constructed using GR, which is predominantly cytoplasmic prior to ligand stimulation. A protocol for designing these chimeras has been Agler et al.
developed by Martinez and Hager. 45 Using the methods we have developed and optimized for transient expression of GR and applied to AR in COS-7 cells, the possibility exists of identifying modulators, both agonists and antagonists of orphan nuclear receptors. The complexity of steroid receptor function and protein interactions, as well as the tissue-specific recruitment of coactivators and corepressors, poses a challenge to drug discovery in identifying nonsteroidal receptor modulators.
Successful identification of leads for drug discovery requires a panel of assays that trace the mechanism of action of a target pathway. 46 , 47 We conclude here that, for a small set of known ligands, ligand affinity as indicated by the FP assay correlates well with potency in the HCS translocation assay. Previous HTS experience with biochemical screens suggests that identification of binders does not always predict cellular activity, as an isolated protein screen will identify moieties that are not selective to the target or not cell permeable. 47 A screening effort using an HCS translocation assay would be expected to identify compounds that not only bind to GR but also promote translocation. However, leads identified in this assay would contain a mixture of agonists and antagonists, which could be triaged with the reporter transactivation assay run in both agonist-and antagonist-seeking mode. However, reporter assays may not be receptor dependent (receptorindependent activation), and cytotoxic compounds can show up as false positives in antagonist assays or as false negatives in agonist assays. HCS assays provide other information unavailable from FP and reporter assays, such as subcellular localization where protein-protein interactions occur. Within this assay triage strategy, the HCS translocation assay provides an inexpensive assay format compared to purchasing commercially available reagents for FP and reporter assays. Ideally, depending on the goal of a screening campaign, multiple assay formats should be used during the hit identification and evaluation process.
Although stable cell lines are an advantage for screening, many times the overexpressed receptor can be toxic to the cell. We have demonstrated that the transient approach is both reproducible and robust, and it can be run in a 384-well plate format. Scaling up transient transfections for HTS, although complex, has been performed for reporter assays. 48, 49 Previous studies using GFP-GR have shown that when GFP-GR is expressed in living cells, it is competent for normal transactivation of GR-responsive promoter activity. 15, 16, 50 The unliganded GFP-GR localizes in the cytoplasm and translocates to the nucleus in a hormone-dependent manner similar to that of the native GR receptor, which is in agreement with our observation presented in this article. All these support the biological relevance of the overexpressed system most researchers use in the field. 50, 51 Our assay system has the potential to be modified using viral-based methods for more efficient expression in target-specific cell lines. 52 It may also be possible to multiplex different color variants of fluorescent proteins tagged to different NRs to investigate heterodimer formation and the dynamics of nuclear-cytoplasmic shuttling using our system. The limitation of running an HCS translocation assay in an HTS mode is not the cell production or the data analysis but the HCS imager scanning speed.
Using high-content imaging technologies, the nongenomic function of the GR receptor-such as effects on G-protein-coupled receptors, mitogen-activated protein kinases, Wnt signaling, and transforming growth factor β family, to name a few-can be multiplexed with GR translocation to begin to understand the signaling pathways that are induced by ligand activation. [53] [54] [55] [56] Newer high-resolution, confocal, high-throughput imaging platforms with advanced image analysis algorithms will also enable the development of nuclear receptor signaling panels, selectivity assays, membrane signaling events, and HTS assays for drug discovery in an automated high-throughput mode. 57 
